- BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine.
- In Q1 FY22, BioNTech and its partner Pfizer Inc (NYSE:PFE) have invoiced approximately 750 million COVID-19 vaccine doses.
- As of end-April 2022, the companies have signed orders for approximately 2.4 billion doses in 2022 and are on track to deliver more than 2 billion doses of COVID-19 vaccine to low- and middle-income countries by the end of 2022.
- BioNTech generated an operating income of €4.75 billion, compared to €1.67 billion a year ago.
- Net profit more than doubled to €3.69 billion versus €1.13 billion. Cash and cash equivalents stood at €6.16 billion.
- Outlook: BioNTech reaffirms FY22 COVID-19 vaccine revenues of €13 billion - €17 billion.
- Price Action: BNTX shares are trading 0.99% higher at $137.52 during the premarket session on Monday's last check.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks